Americans diagnosed with hypothyroidism and their clinical providers now have access to greater dosage flexibility within levothyroxine therapy, with three new dosage strengths of levothyroxine sodium oral solution now available to treat hypothyroidism. IBSA Pharma markets the drug as Tirosint®-SOL. The unique new dosing options – 37.5, 44 and 62.5 micrograms – are a first...
HealthPartners Institute’s International Diabetes Center (IDC) recently developed and piloted a process for incorporating patients’ continuous glucose monitoring (CGM) data directly into the electronic health record (EHR), improving clinician access to glucose information. During a presentation at the American Diabetes Association’s 81st Scientific Sessions, IDC medical director Amy Criego, MD, described this process for integrating...
Imposter syndrome – the belief that you do not belong or that you are not good enough – is more common that people think, especially in the medical field. Endocrine News spoke to experts on this dilemma who discuss common solutions to get past these feelings of self-doubt. Some of the most well-known and...
The U.S. Food and Drug Administration this week cleared Abbott’s FreeStyle® Libre 2 iOS application for use with compatible iPhones, to pair with its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Approved for adults and children (4 and older) with diabetes, the new app enables users to get glucose readings directly on their...
[Editor’s Note: This post has been updated to include comments from Rita Kalyani, MD.] When the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product last month, many were hailing this as a breakthrough in treating diabetes. The impacts could be immediately felt by people rationing their insulin due to cost as...
Teamwork is often vital to improving patient outcomes. And while most healthcare professionals are in favor of working together, the biggest obstacle appears to be simply finding the time to team up. In a survey conducted last summer by the market research and analytics company The Harris Poll for Boehringer Ingelheim and Eli Lilly and...
New pooled data from Phase 2 and Phase 3 clinical trials further reinforce that teprotumumab-trbw significantly improves proptosis (eye bulging) and diplopia (double vision) for thyroid eye disease (TED) in patients in different subgroups, with most maintaining a long-term response. The results were published recently in The Lancet Diabetes & Endocrinology. Teprotumumab-trbw is a fully human...
Three in four patients say telehealth quality of care is similar to in-person visits Two-thirds of patients with chronic endocrine health problems who need close monitoring say they would like to continue with telemedicine follow-up visits after the COVID-19 pandemic ends, according to a survey presented virtually at ENDO 2021. Three-quarters of providers also said...
The U.S. Food and Drug Administration this week cleared Abbott’s FreeStyle® Libre 2 iOS application for use with compatible iPhones, to pair with its FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) system. Approved for adults and children (4 and older) with diabetes, the new app enables users to get glucose readings directly on their...
